#Drug Development

Articles (11)

• 🇺🇸 Plus Therapeutics names Eric Daniels as chief development officer — 09/04/2026 [USA] Related: #Executive Appointment, #Biotechnology
• 🇺🇸 Novartis shells out $2 billion for immunology biotech Excellergy, in second multi-billion dollar deal in a week — 27/03/2026 [USA]

  The Swiss pharma giant is betting on a next-generation allergy treatment that may prove to work faster and better than anything currently on the market.

  Related: #Pharmaceutical M&A, #Patent Expirations
• 🇺🇸 Immunic at Leerink Global Healthcare Conference: Strategic Insights on MS Drug — 11/03/2026 [USA] Related: #Biotech Conference
• 🇺🇸 Citizens raises Prelude Therapeutics price target on JAK2 potential — 11/03/2026 [USA] Related: #Biotech Investment
• 🇺🇸 Olema earnings loom as analysts eye palazestrant potential — 08/03/2026 [USA] Related: #Earnings
• 🇺🇸 Savara receives FDA day 74 letter for autoimmune PAP drug — 06/03/2026 [USA] Related: #FDA Regulation
• 🇺🇸 BBOT publishes preclinical data on panKRAS inhibitor BBO-11818 — 06/03/2026 [USA] Related: #Oncology
• 🇺🇸 Disc Medicine announces workforce reduction and restructuring plan — 27/02/2026 [USA] Related: #Pharmaceutical Industry, #Restructuring, #FDA, #Financial Performance
• 🇺🇸 Bicara Therapeutics prices $150 million stock offering at $16 — 25/02/2026 [USA] Related: #Biopharmaceutical Financing, #Stock Offering, #Cancer Treatment
• 🇺🇸 Vanda Pharmaceuticals stock surges after the FDA approves its new Bipolar I drug — 21/02/2026 [USA] Related: #Pharmaceutical Approval, #Stock Market Reaction, #Intellectual Property
• 🇺🇸 FDA will drop two-study requirement for new drug approvals, aiming to speed access — 18/02/2026 [USA]

  The Food and Drug Administration plans to drop its longtime standard of requiring two rigorous studies to win approval for new drugs, the latest change from Trump administration officials vowing to sp...

  Related: #Regulatory Reform, #Healthcare Policy